![]() | |
Clinical data | |
---|---|
Trade names | Hengqu |
Other names | Rafutrombopag olamine; rafutrombopag ethanolamine; hetrombopag; SHR-8735; SHR8735 |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H22N4O5 |
Molar mass | 458.474 g·mol−1 |
3D model ( JSmol) | |
| |
|
Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia. [1] [2] [3]
It is a non-peptide small‐molecule thrombopoietin receptor agonist. [4]
In China, it is approved for second-line treatment for primary immune thrombocytopenic purpura (ITP) and severe aplastic anemia (SAA) in adults. [4]
![]() | |
Clinical data | |
---|---|
Trade names | Hengqu |
Other names | Rafutrombopag olamine; rafutrombopag ethanolamine; hetrombopag; SHR-8735; SHR8735 |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H22N4O5 |
Molar mass | 458.474 g·mol−1 |
3D model ( JSmol) | |
| |
|
Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia. [1] [2] [3]
It is a non-peptide small‐molecule thrombopoietin receptor agonist. [4]
In China, it is approved for second-line treatment for primary immune thrombocytopenic purpura (ITP) and severe aplastic anemia (SAA) in adults. [4]